No advantage of A42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studiesSYMBOLSYMBOL

Authors :: Szekely, C A.
Green, R C.
Breitner, J C.S.
Østbye, T
Beiser, A S.
Corrada, M M.
Dodge, H H.
Ganguli, M
Kawas, C H.
Kuller, L H.
Psaty, B M.
Resnick, S M.
Wolf, P A.
Zonderman, A B.
Welsh-Bohmer, K A.
Zandi, P P.
Source :: Neurology (Ovid); June 2008, Vol. 70 Issue: 24 p2291-2298, 8p
Publication Year :: 2008
Abstract: Observational studies show reduced incidence of Alzheimer dementia (AD) in users of nonsteroidal anti-inflammatory drugs (NSAIDs). One hypothesis holds that the subset of NSAIDs known as selective A42-lowering agents (SALAs) is responsible for this apparent reduction in AD risk.

Full Text Access

Tools